Fever of Unknown Origin – a Literature Review
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Communicable Disease Toolkit Liberia
WHO/CDS/2004.24 COMMUNICABLE DISEASE TOOLKIT LIBERIA 1. COMMUNICABLE DISEASE PROFILE World Health Organization 2004 Communicable Disease Working Group on Emergencies, WHO/HQ The WHO Regional Office for Africa (AFRO) WHO Office, Liberia © World Health Organization 2004 All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use. Further information is available at: CDS Information Resource Centre, World Health Organization, 1211 Geneva 27, Switzerland; fax: (+41) 22 791 4285, e-mail: [email protected] Communicable Disease Toolkit for LIBERIA 2004: Communicable Disease Profile. ACKNOWLEDGMENTS Edited by Dr Michelle Gayer, Dr Katja Schemionek, Dr Monica Guardo, and Dr Máire Connolly of the Programme on Communicable Diseases in Complex Emergencies, WHO/CDS. This Profile is a collaboration between the Communicable Disease Working Group on Emergencies (CD-WGE) at WHO/HQ, the Division of Communicable Disease Prevention and Control (DCD) at WHO/AFRO and the Office of the WHO Representative for Liberia. -
Medical Management of Biological Casualties Handbook
USAMRIID’s MEDICAL MANAGEMENT OF BIOLOGICAL CASUALTIES HANDBOOK Sixth Edition April 2005 U.S. ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES FORT DETRICK FREDERICK, MARYLAND Emergency Response Numbers National Response Center: 1-800-424-8802 or (for chem/bio hazards & terrorist events) 1-202-267-2675 National Domestic Preparedness Office: 1-202-324-9025 (for civilian use) Domestic Preparedness Chem/Bio Helpline: 1-410-436-4484 or (Edgewood Ops Center – for military use) DSN 584-4484 USAMRIID’s Emergency Response Line: 1-888-872-7443 CDC'S Emergency Response Line: 1-770-488-7100 Handbook Download Site An Adobe Acrobat Reader (pdf file) version of this handbook can be downloaded from the internet at the following url: http://www.usamriid.army.mil USAMRIID’s MEDICAL MANAGEMENT OF BIOLOGICAL CASUALTIES HANDBOOK Sixth Edition April 2005 Lead Editor Lt Col Jon B. Woods, MC, USAF Contributing Editors CAPT Robert G. Darling, MC, USN LTC Zygmunt F. Dembek, MS, USAR Lt Col Bridget K. Carr, MSC, USAF COL Ted J. Cieslak, MC, USA LCDR James V. Lawler, MC, USN MAJ Anthony C. Littrell, MC, USA LTC Mark G. Kortepeter, MC, USA LTC Nelson W. Rebert, MS, USA LTC Scott A. Stanek, MC, USA COL James W. Martin, MC, USA Comments and suggestions are appreciated and should be addressed to: Operational Medicine Department Attn: MCMR-UIM-O U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Fort Detrick, Maryland 21702-5011 PREFACE TO THE SIXTH EDITION The Medical Management of Biological Casualties Handbook, which has become affectionately known as the "Blue Book," has been enormously successful - far beyond our expectations. -
Dengue and Yellow Fever
GBL42 11/27/03 4:02 PM Page 262 CHAPTER 42 Dengue and Yellow Fever Dengue, 262 Yellow fever, 265 Further reading, 266 While the most important viral haemorrhagic tor (Aedes aegypti) as well as reinfestation of this fevers numerically (dengue and yellow fever) are insect into Central and South America (it was transmitted exclusively by arthropods, other largely eradicated in the 1960s). Other factors arboviral haemorrhagic fevers (Crimean– include intercontinental transport of car tyres Congo and Rift Valley fevers) can also be trans- containing Aedes albopictus eggs, overcrowding mitted directly by body fluids. A third group of of refugee and urban populations and increasing haemorrhagic fever viruses (Lassa, Ebola, Mar- human travel. In hyperendemic areas of Asia, burg) are only transmitted directly, and are not disease is seen mainly in children. transmitted by arthropods at all. The directly Aedes mosquitoes are ‘peri-domestic’: they transmissible viral haemorrhagic fevers are dis- breed in collections of fresh water around the cussed in Chapter 41. house (e.g. water storage jars).They feed on hu- mans (anthrophilic), mainly by day, and feed re- peatedly on different hosts (enhancing their role Dengue as vectors). Dengue virus is numerically the most important Clinical features arbovirus infecting humans, with an estimated Dengue virus may cause a non-specific febrile 100 million cases per year and 2.5 billion people illness or asymptomatic infection, especially in at risk.There are four serotypes of dengue virus, young children. However, there are two main transmitted by Aedes mosquitoes, and it is un- clinical dengue syndromes: dengue fever (DF) usual among arboviruses in that humans are the and dengue haemorrhagic fever (DHF). -
Overview of Fever of Unknown Origin in Adult and Paediatric Patients L
Overview of fever of unknown origin in adult and paediatric patients L. Attard1, M. Tadolini1, D.U. De Rose2, M. Cattalini2 1Infectious Diseases Unit, Department ABSTRACT been proposed, including removing the of Medical and Surgical Sciences, Alma Fever of unknown origin (FUO) can requirement for in-hospital evaluation Mater Studiorum University of Bologna; be caused by a wide group of dis- due to an increased sophistication of 2Paediatric Clinic, University of Brescia eases, and can include both benign outpatient evaluation. Expansion of the and ASST Spedali Civili di Brescia, Italy. and serious conditions. Since the first definition has also been suggested to Luciano Attard, MD definition of FUO in the early 1960s, include sub-categories of FUO. In par- Marina Tadolini, MD Domenico Umberto De Rose, MD several updates to the definition, di- ticular, in 1991 Durak and Street re-de- Marco Cattalini, MD agnostic and therapeutic approaches fined FUO into four categories: classic Please address correspondence to: have been proposed. This review out- FUO; nosocomial FUO; neutropenic Marina Tadolini, MD, lines a case report of an elderly Ital- FUO; and human immunodeficiency Via Massarenti 11, ian male patient with high fever and virus (HIV)-associated FUO, and pro- 40138 Bologna, Italy. migrating arthralgia who underwent posed three outpatient visits and re- E-mail: [email protected] many procedures and treatments before lated investigations as an alternative to Received on November 27, 2017, accepted a final diagnosis of Adult-onset Still’s “1 week of hospitalisation” (5). on December, 7, 2017. disease was achieved. This case report In 1997, Arnow and Flaherty updated Clin Exp Rheumatol 2018; 36 (Suppl. -
Epinotes Disease Surveillance Newsletter
June 2019 Florida Department of Health - Hillsborough County EpiNotes Disease Surveillance Newsletter Director Douglas Holt, MD 813.307.8008 Articles and Attachments Included This Month Medical Director (HIV/STD/EPI) Health Advisories and Alerts 1 Charurut Somboonwit, MD 813.307.8008 May 2019 Reportable Disease Summary 2 Medical Director (TB/Refugee) Florida Food Recalls 5 Beata Casanas, MD 813.307.8008 CDC Vaccine Schedules App for Healthcare Providers 5 Medical Director (Vaccine Outreach) County Influenza Report 6 Jamie P. Morano, MD, MPH CDC Health Advisory #420 7 813.307.8008 National HIV Testing Day 10 Community Health Director Leslene Gordon, PhD, RD, LD/N Candida auris Update 13 813.307.8015 x7107 Arboviral Clinician Letter and One Pagers 15 Disease Control Director Carlos Mercado, MBA Reportable Diseases/Conditions in Florida, Practitioner List 23 813.307.8015 x6321 FDOH, Practitioner Disease Report Form 24 Environmental Administrator Brian Miller, RS 813.307.8015 x5901 Health Advisories, News, and Alerts Epidemiology Michael Wiese, MPH, CPH 813.307.8010 Fax 813.276.2981 • CDC Health Advisory #420: Nationwide Shortage of Tuberculin Skin Test Antigens: CDC Recommendations for Patient Care and TO REPORT A DISEASE: Public Health Practice Epidemiology 813.307.8010 • CDC Travel Notices: • Global Measles Outbreak Notice - Measles is in many After Hours Emergency 813.307.8000 countries and outbreaks of the disease are occurring around the world. Before you travel internationally, regardless of HIV/AIDS Surveillance where you are going, make sure you are protected fully Erica Botting against measles. If you are not sure, see your healthcare 813.307.8011 provider at least one month before your scheduled departure. -
Oklahoma Disease Reporting Manual
Oklahoma Disease Reporting Manual List of Contributors Acute Disease Service Lauri Smithee, Chief Laurence Burnsed Anthony Lee Becky Coffman Renee Powell Amy Hill Jolianne Stone Christie McDonald Jeannie Williams HIV/STD Service Jan Fox, Chief Kristen Eberly Terrainia Harris Debbie Purton Janet Wilson Office of the State Epidemiologist Kristy Bradley, State Epidemiologist Public Health Laboratory Garry McKee, Chief Robin Botchlet John Murray Steve Johnson Table of Contents Contact Information Acronyms and Jargon Defined Purpose and Use of Disease Reporting Manual Oklahoma Disease Reporting Statutes and Rules Oklahoma Statute Title 63: Public Health and Safety Article 1: Administration Article 5: Prevention and Control of Disease Oklahoma Administrative Code Title 310: Oklahoma State Department of Health Chapter 515: Communicable Disease and Injury Reporting Chapter 555: Notification of Communicable Disease Risk Exposure Changes to the Communicable Disease and Injury Reporting Rules To Which State Should You Report a Case? Public Health Investigation and Disease Detection of Oklahoma (PHIDDO) Public Health Laboratory Oklahoma State Department of Health Laboratory Services Electronic Public Health Laboratory Requisition Disease Reporting Guidelines Quick Reference List of Reportable Infectious Diseases by Service Human Immunodeficiency Virus (HIV) Infection and Acquired Immunodeficiency Syndrome (AIDS) Anthrax Arboviral Infection Bioterrorism – Suspected Disease Botulism Brucellosis Campylobacteriosis CD4 Cell Count < 500 Chlamydia trachomatis, -
Nunavut Communicable Disease and Surveillance Manual
Nunavut Communicable Disease and Surveillance Manual Contents 1.0 Introduction 2.0 Public Health Investigation, Management and Reporting of Communicable Diseases and Outbreaks in Nunavut 2.1 Legislative Authority 2.2 Communicable Disease Surveillance and Follow-up 3.0 Outbreak Management Guidelines 3.1 Principles of Outbreak Management 3.2 Outbreak Team 3.3 Roles and Responsibilities of Outbreak Team Members 3.4 Steps in Outbreak Investigation and Management 4.0 Enteric, Food, and Waterborne Infections 4.1 Amoebiasis 4.2 Botulism 4.3 Campylobacteriosis 4.4 Cholera 4.5 Cryptosporidiosis 4.6 Cyclosporiasis 4.7 Giardiasis 4.8 Hepatitis A 4.9 Listeriosis 4.10 Norovirus 4.11 Paralytic Shellfish Poisoning 4.12 Paratyphoid 4.13 Salmonellosis 4.14 Shigellosis 4.15 Trichinosis 4.16 Typhoid 4.17 Verotoxigenic Escherichia coli 4.18 Yersiniosis Nunavut Communicable Disease Manual (May 2016) Page 1 of 3 5.0 Blood-Borne Infections 5.1 Acquired Immunodeficiency Syndrome and Human Immunodeficiency Virus Infection 5.2 Blood and Body Fluid Exposure 5.3 Hepatitis B 5.4 Hepatitis C 5.5 Human T-cell Lymphotrophic Virus 6.0 Sexually Transmitted Infections 6.1 Chancroid 6.2 Chlamydia 6.3 Gonorrhea 6.4 Syphilis 7.0 Vaccine Preventable Infections 7.1 Diphtheria 7.2 Human Papillomavirus 7.3 Invasive Haemophilus influenzae 7.4 Disease Measles 7.5 Mumps 7.6 Pertussis 7.7 Poliomyelitis 7.8 Rubella 7.9 Rubella, Congenital 7.10 Smallpox 7.11 Tetanus 7.12 Varicella 8.0 Infections Spread By Direct Contact 8.1 Group B Streptococcal Disease Methicillin- 8.2 Resistant Staphylococcus -
Yellow Fever
Infectious Disease Epidemiology Section Office of Public Health, Louisiana Dept of Health & Hospitals 800-256-2748 (24 hr. number), (504) 568-8313 www.infectiousdisease.dhh.louisiana Yellow Fever Revised 06/03/2016 Yellow fever is caused by a Flavivirus (the family which includes dengue, West Nile, Saint Louis en- cephalitis and Japanese encephalitis) Epidemiology Yellow fever is transmitted by Aedes aegypti and other mosquitoes. It is naturally occurring in Africa and South America, but the anthroponotic (vector-borne person-to-person) transmission of the virus may oc- cur wherever a suitable vector is present (Figure). Figure: Yellow Fever Endemic Zones in Africa (left) and South America (right) In the southern United States where A. aegypti is present, epidemics of urban yellow fever occurred. Yel- low fever was transmitted by A. aegypti mosquitoes that are infected after feeding on viremic humans and then spread the infection in subsequent feeding attempts. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Louisiana Office of Public Health – Infectious Disease Epidemiology Section- Epidemiology Manual Page 1 of 5 Urban cycle The urban cycle involves human hosts and A.aegypti vector. For over 200 years it was a major killer in U.S. port cities (1,000 deaths in the last major epidemic in New Orleans in 1905). Elimination efforts un- dertaken in the early 1900s led to the complete elimination of yellow fever as an urban epidemic in the Americas in the 1930’s (the last urban American cases occurred in northeastern Brazil). This was one of the most successful eradication campaigns in public health. Sylvatic cycle The sylvatic cycle involves forest primates, principally monkeys and forest canopy mosquitoes. -
Uživatel:Zef/Output18
Uživatel:Zef/output18 < Uživatel:Zef rozřadit, rozdělit na více článků/poznávaček; Název !! Klinický obraz !! Choroba !! Autor Bárányho manévr; Bonnetův manévr; Brudzinského manévr; Fournierův manévr; Fromentův manévr; Heimlichův manévr; Jendrassikův manévr; Kernigův manévr; Lasčgueův manévr; Müllerův manévr; Scanzoniho manévr; Schoberův manévr; Stiborův manévr; Thomayerův manévr; Valsalvův manévr; Beckwithova známka; Sehrtova známka; Simonova známka; Svěšnikovova známka; Wydlerova známka; Antonovo znamení; Apleyovo znamení; Battleho znamení; Blumbergovo znamení; Böhlerovo znamení; Courvoisierovo znamení; Cullenovo znamení; Danceovo znamení; Delbetovo znamení; Ewartovo znamení; Forchheimerovo znamení; Gaussovo znamení; Goodellovo znamení; Grey-Turnerovo znamení; Griesingerovo znamení; Guddenovo znamení; Guistovo znamení; Gunnovo znamení; Hertogheovo znamení; Homansovo znamení; Kehrerovo znamení; Leserovo-Trélatovo znamení; Loewenbergerovo znamení; Minorovo znamení; Murphyho znamení; Nobleovo znamení; Payrovo znamení; Pembertonovo znamení; Pinsovo znamení; Pleniesovo znamení; Pléniesovo znamení; Prehnovo znamení; Rovsingovo znamení; Salusovo znamení; Sicardovo znamení; Stellwagovo znamení; Thomayerovo znamení; Wahlovo znamení; Wegnerovo znamení; Zohlenovo znamení; Brachtův hmat; Credého hmat; Dessaignes ; Esmarchův hmat; Fritschův hmat; Hamiltonův hmat; Hippokratův hmat; Kristellerův hmat; Leopoldovy hmat; Lepagův hmat; Pawlikovovy hmat; Riebemontův-; Zangmeisterův hmat; Leopoldovy hmaty; Pawlikovovy hmaty; Hamiltonův znak; Spaldingův znak; -
The Diagnostic Approach to Fever of Unknown Origin in Cats*
3 CE CREDITS CE Article 2 The Diagnostic Approach to Fever of Unknown Origin in Cats* ❯❯ Julie Flood, DVM, DACVIM Abstract: Identifying the cause of fever of unknown origin (FUO) in cats is a diagnostic challenge, Antech Diagnostics just as it is in dogs. Infection is the most common cause of FUO in cats. As in dogs, the diagnostic Irvine, California workup can be frustrating, but most FUO causes can eventually be determined. This article address- es the potential diagnostic tests for, and the differential diagnosis and treatment of, FUO in cats. rue fever (pyrexia) is defined as an during the initial workup or responds to increase in body temperature due to antibiotic treatment; therefore, most cats T an elevation of the thermal set point do not have a true FUO.4 in the anterior hypothalamus secondary to the release of pyrogens.1 With hyperther- Differential Diagnosis mic conditions other than true fever, the Information regarding FUO in cats is hypothalamic set point is not adjusted.1 extremely limited, and there are no retro- At a Glance Nonfebrile hyperthermia occurs when heat spective studies. Fevers are common in cats, gain exceeds heat loss, such as with inade- and most diseases associated with FUO Differential Diagnosis quate heat dissipation, exercise, and patho- in cats are infectious.5 Neoplasia is a less Page 26 logic or pharmacologic causes.1 common cause of FUO in cats, and FUO Clinical Approach Cats with true fever typically have body due to immune-mediated disease is rare in Page 26 temperatures between 103°F and 106°F cats.6 FUO causes are often separated into Potential Causes of Fever (39.5°C to 41.1°C).2 Cats are less likely than groups based on the underlying disease of Unknown Origin in Cats dogs to succumb to the dangerous effects mechanism.2,3,7 Most FUOs are caused by a Page 27 of body temperatures greater than 106°F, common disease presenting in an obscure 8 Staged Diagnostic which are usually seen with nonfebrile fashion. -
Yellow Fever
Yellow Fever travel history, i.e., travel to an area of South 1. Case Definition America or Africa endemic for yellow fever in 1.1 Laboratory-Confirmed Case: the past 14 days. Clinical illness* with laboratory confirmation of Note: The Manitoba Health Surveillance infection: Unit monitors naturally acquired yellow Isolation of yellow fever virus (non- fever disease only, not illness resulting vaccine strain) from yellow fever vaccination. Post- OR vaccination illnesses are captured by the Detection of yellow fever virus nucleic AEFI (Adverse Events Following acid in body fluids or tissue (non- Immunization) reporting. vaccine strain) OR 2. Reporting and Other A significant (i.e., fourfold or greater) Requirements rise in antibody titre (using the plaque reduction neutralization test) to the Laboratory: yellow fever virus in the absence of All positive laboratory results are yellow fever vaccination reportable to the Public Health OR Surveillance Unit (204-948-3044 A single elevated yellow fever virus secure fax). IgM antibody titre in the absence of Health Professional: yellow fever vaccination within the Probable (clinical) cases of yellow previous two months (1). fever are reportable to the Public Health Surveillance Unit by telephone 1.2 Probable Case: (204-788-6736) during regular hours Clinical illness* with laboratory evidence of (8:30 a.m. to 4:30 p.m.) AND by infection: secure fax (204-948-3044) on the A stable elevated antibody titre to same day that they are identified. yellow fever virus with no other known After hours telephone reporting is to cause the Medical Officer of Health on call at AND (204-788-8666). -
Fever of Unknown Origin in Childhood: Difficulties in Diagnosis
Annals of the Rheumatic Diseases 1994; 53: 429-433 429 MASTERCLASS Ann Rheum Dis: first published as 10.1136/ard.53.7.429 on 1 July 1994. Downloaded from Fever of unknown origin in childhood: difficulties in diagnosis Katherine Martin, E Graham Davies, John S Axford Case report (CRP) 208 mg/I. Liver function tests were A twelve year old white boy presented to abnormal: alanine transaminase 91 IUAL another hospital with a two month history of (normal range 1-40), gamma glutamyl intermittent fever with night sweats, general transferase 134 IUAL (normal range 0-60), malaise, arthralgia and myalgia. He had bilirubin 18 micromolVL (0-17), alkaline marked cervical lymphadenopathy. Latex phosphatase 217 IU/L (30-100) and albumin agglutination for toxoplasma antibodies was 18 g/l (35-45). Renal impairment was apparent positive at a dilution of 1/128. A diagnosis of with a raised serum creatinine (224 micromol/ acquired toxoplasmosis was made and sulpha- L (60-110)). Chest radiograph showed right diazine 1 g four times a day, trimethoprim 300 middle lobe consolidation. Abdominal mg twice a day and folinic acid 15 mg ultrasound scan (USS) confirmed hepato- alternative days, were started. Over the next splenomegaly and ascites. Echocardiogram week he developed a generalised urticarial rash, showed a small pericardial effusion. peripheral oedema and profuse bloody A diagnosis of Stevens-Johnson syndrome diarrhoea and was referred to our unit. with acute renal failure and disseminated On examination he was delirious with a intravascular coagulation (DIC) was made. persistent fever of up to 42°C and he was Supportive therapy, broad spectrum anti- bleeding from his nose and mouth.